• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

作为 GSK3β 抑制剂的恶二唑衍生物的对接和定量构效关系。

Docking and quantitative structure-activity relationship of oxadiazole derivates as inhibitors of GSK3β.

机构信息

Centro de Bioinformática y Simulación Molecular, Facultad de Ingeniería, Universidad de Talca, 2 Norte 685, Casilla 721, Talca, Chile.

出版信息

Mol Divers. 2014 Feb;18(1):149-59. doi: 10.1007/s11030-013-9483-5. Epub 2013 Oct 1.

DOI:10.1007/s11030-013-9483-5
PMID:24081608
Abstract

The binding modes of 42 oxadiazole derivates inside glycogen synthase kinase 3 beta (GSK3β were determined using docking experiments; thus, the preferred active conformations of these inhibitors are proposed. We found that these compounds adopt a scorpion-shaped conformation and they accept a hydrogen bond (HB) from the residue Val135 of the GSK3β ATP-binding site hinge region. In addition, quantitative structure-activity relationship (QSAR) models were constructed to explain the trend of the GSK3β inhibitory activities for the studied compounds. In a first approach, three-dimensional (3D) vectors were calculated using docking conformations and, by using multiple-linear regression, we assessed that GETAWAY vectors were able to describe the reported biological activities. In other QSAR approach, SMILES-based optimal descriptors were calculated. The best model included three-SMILES elements SSSβ leading to the identification of key molecular features that contribute to a high GSK3β inhibitory activity.

摘要

使用对接实验确定了 42 种恶二唑衍生物在糖原合酶激酶 3β(GSK3β)内的结合模式;因此,提出了这些抑制剂的优选活性构象。我们发现这些化合物采用了蝎子形状的构象,并且它们接受来自 GSK3β ATP 结合位点铰链区域残基 Val135 的氢键 (HB)。此外,还构建了定量构效关系 (QSAR) 模型,以解释所研究化合物对 GSK3β 抑制活性的趋势。在第一种方法中,使用对接构象计算了三维 (3D) 向量,并且通过多元线性回归,我们评估了 GETAWAY 向量能够描述报道的生物学活性。在另一种 QSAR 方法中,计算了基于 SMILES 的最佳描述符。最佳模型包括三个 SMILES 元素 SSSβ,从而确定了有助于高 GSK3β 抑制活性的关键分子特征。

相似文献

1
Docking and quantitative structure-activity relationship of oxadiazole derivates as inhibitors of GSK3β.作为 GSK3β 抑制剂的恶二唑衍生物的对接和定量构效关系。
Mol Divers. 2014 Feb;18(1):149-59. doi: 10.1007/s11030-013-9483-5. Epub 2013 Oct 1.
2
Insights into the interactions between maleimide derivates and GSK3β combining molecular docking and QSAR.结合分子对接和定量构效关系深入了解马来酰亚胺衍生物与糖原合成酶激酶3β之间的相互作用。
PLoS One. 2014 Jul 10;9(7):e102212. doi: 10.1371/journal.pone.0102212. eCollection 2014.
3
Binding studies and quantitative structure-activity relationship of 3-amino-1H-indazoles as inhibitors of GSK3β.3-氨基-1H-吲唑类化合物作为 GSK3β 抑制剂的结合研究与定量构效关系。
Chem Biol Drug Des. 2011 Oct;78(4):631-41. doi: 10.1111/j.1747-0285.2011.01186.x. Epub 2011 Aug 25.
4
In silico design novel (5-imidazol-2-yl-4-phenylpyrimidin-2-yl)[2-(2-pyridylamino)ethyl]amine derivatives as inhibitors for glycogen synthase kinase 3 based on 3D-QSAR, molecular docking and molecular dynamics simulation.基于 3D-QSAR、分子对接和分子动力学模拟,设计新型(5-咪唑-2-基-4-苯基嘧啶-2-基)[2-(2-吡啶基氨基)乙基]胺衍生物作为糖原合酶激酶 3 的抑制剂。
Comput Biol Chem. 2020 Oct;88:107328. doi: 10.1016/j.compbiolchem.2020.107328. Epub 2020 Jul 4.
5
Theoretical Studies on the Selectivity Mechanisms of Glycogen Synthase Kinase 3β (GSK3β) with Pyrazine ATP-competitive Inhibitors by 3DQSAR, Molecular Docking, Molecular Dynamics Simulation and Free Energy Calculations.基于三维定量构效关系、分子对接、分子动力学模拟和自由能计算对糖原合酶激酶3β(GSK3β)与吡嗪类ATP竞争性抑制剂选择性机制的理论研究
Curr Comput Aided Drug Des. 2020;16(1):17-30. doi: 10.2174/1573409915666190708102459.
6
2-{3-[4-(Alkylsulfinyl)phenyl]-1-benzofuran-5-yl}-5-methyl-1,3,4-oxadiazole derivatives as novel inhibitors of glycogen synthase kinase-3beta with good brain permeability.2-{3-[4-(烷基亚磺酰基)苯基]-1-苯并呋喃-5-基}-5-甲基-1,3,4-恶二唑衍生物作为具有良好脑渗透性的新型糖原合酶激酶-3β抑制剂。
J Med Chem. 2009 Oct 22;52(20):6270-86. doi: 10.1021/jm900647e.
7
Structural basis of valmerins as dual inhibitors of GSK3β/CDK5.作为 GSK3β/CDK5 的双重抑制剂,瓦美灵的结构基础。
J Mol Model. 2014 Sep;20(9):2407. doi: 10.1007/s00894-014-2407-1. Epub 2014 Aug 21.
8
A rational approach to selective pharmacophore designing: an innovative strategy for specific recognition of Gsk3β.一种合理的选择药效团设计方法:特异性识别 Gsk3β 的创新策略。
Mol Divers. 2012 Aug;16(3):553-62. doi: 10.1007/s11030-012-9387-9. Epub 2012 Aug 24.
9
Design, synthesis and structure-activity relationships of 1,3,4-oxadiazole derivatives as novel inhibitors of glycogen synthase kinase-3beta.1,3,4-恶二唑衍生物作为糖原合酶激酶-3β新型抑制剂的设计、合成及构效关系
Bioorg Med Chem. 2009 Mar 1;17(5):2017-29. doi: 10.1016/j.bmc.2009.01.019. Epub 2009 Jan 15.
10
Structure-activity relationship of the 7-hydroxy benzimidazole analogs as glycogen synthase kinase 3β inhibitor.7-羟基苯并咪唑类似物作为糖原合成酶激酶 3β抑制剂的构效关系。
Bioorg Med Chem Lett. 2012 Mar 1;22(5):1891-4. doi: 10.1016/j.bmcl.2012.01.065. Epub 2012 Jan 28.

引用本文的文献

1
Biological and Phytochemical Insights Into (L.) Mill: Cytotoxic, Wound-Healing, and Anti-Aging Potentials.对(L.)Mill的生物学和植物化学见解:细胞毒性、伤口愈合及抗衰老潜力
Food Sci Nutr. 2025 Jun 17;13(6):e70399. doi: 10.1002/fsn3.70399. eCollection 2025 Jun.
2
JAZ is essential for ligand specificity of the COI1/JAZ co-receptor.JAZ 对于 COI1/JAZ 共受体的配体特异性是必需的。
Proc Natl Acad Sci U S A. 2022 Dec 6;119(49):e2212155119. doi: 10.1073/pnas.2212155119. Epub 2022 Nov 29.
3
Computational Modeling to Explain Why 5,5-Diarylpentadienamides are TRPV1 Antagonists.

本文引用的文献

1
Synthesis, in silico, in vitro, and in vivo investigation of 5-[¹¹C]methoxy-substituted sunitinib, a tyrosine kinase inhibitor of VEGFR-2.5-[¹¹C]甲氧基取代舒尼替尼的合成、计算机模拟、体外和体内研究,一种 VEGFR-2 的酪氨酸激酶抑制剂。
Eur J Med Chem. 2012 Dec;58:272-80. doi: 10.1016/j.ejmech.2012.10.020. Epub 2012 Oct 23.
2
Structure-based optimization of oxadiazole-based GSK-3 inhibitors.基于结构的恶二唑类糖原合成酶激酶-3抑制剂的优化
Eur J Med Chem. 2013 Mar;61:26-40. doi: 10.1016/j.ejmech.2012.06.006. Epub 2012 Jun 12.
3
Molecular dynamics of protein kinase-inhibitor complexes: a valid structural information.
用于解释5,5-二芳基戊二烯酰胺为何是瞬时受体电位香草酸亚型1(TRPV1)拮抗剂的计算模型
Molecules. 2021 Mar 21;26(6):1765. doi: 10.3390/molecules26061765.
4
Design, synthesis, structure, in vitro cytotoxic activity evaluation and docking studies on target enzyme GSK-3β of new indirubin-3'-oxime derivatives.新型靛玉红-3'-肟衍生物的设计、合成、结构、对靶酶 GSK-3β 的体外细胞毒性活性评价及对接研究。
Sci Rep. 2020 Jul 10;10(1):11429. doi: 10.1038/s41598-020-68134-8.
5
Structural Requirements of -alpha-Mercaptoacetyl Dipeptide (NAMdP) Inhibitors of Virulence Factor LasB: 3D-QSAR, Molecular Docking, and Interaction Fingerprint Studies.结构要求的 -alpha- 巯基乙酰二肽(NAMdP)抑制剂的毒力因子 LasB:3D-QSAR、分子对接和相互作用指纹研究。
Int J Mol Sci. 2019 Dec 5;20(24):6133. doi: 10.3390/ijms20246133.
6
Docking, Interaction Fingerprint, and Three-Dimensional Quantitative Structure-Activity Relationship (3D-QSAR) of Sigma1 Receptor Ligands, Analogs of the Neuroprotective Agent RC-33.西格玛1受体配体(神经保护剂RC-33的类似物)的对接、相互作用指纹图谱及三维定量构效关系(3D-QSAR)
Front Chem. 2019 Jul 11;7:496. doi: 10.3389/fchem.2019.00496. eCollection 2019.
7
Theoretical Studies on the Selectivity Mechanisms of Glycogen Synthase Kinase 3β (GSK3β) with Pyrazine ATP-competitive Inhibitors by 3DQSAR, Molecular Docking, Molecular Dynamics Simulation and Free Energy Calculations.基于三维定量构效关系、分子对接、分子动力学模拟和自由能计算对糖原合酶激酶3β(GSK3β)与吡嗪类ATP竞争性抑制剂选择性机制的理论研究
Curr Comput Aided Drug Des. 2020;16(1):17-30. doi: 10.2174/1573409915666190708102459.
8
Mycobacterium tuberculosis serine/threonine protein kinases: structural information for the design of their specific ATP-competitive inhibitors.结核分枝杆菌丝氨酸/苏氨酸蛋白激酶:设计其特异性 ATP 竞争抑制剂的结构信息。
J Comput Aided Mol Des. 2018 Dec;32(12):1315-1336. doi: 10.1007/s10822-018-0173-3. Epub 2018 Oct 26.
9
Insights into the Structural Requirements of 2(S)-Amino-6-Boronohexanoic Acid Derivatives as Arginase I Inhibitors: 3D-QSAR, Docking, and Interaction Fingerprint Studies.2(S)-氨基-6-硼代己酸衍生物作为精氨酸酶 I 抑制剂的结构要求的深入了解:3D-QSAR、对接和相互作用指纹研究。
Int J Mol Sci. 2018 Sep 28;19(10):2956. doi: 10.3390/ijms19102956.
10
Flavonoids as CDK1 Inhibitors: Insights in Their Binding Orientations and Structure-Activity Relationship.黄酮类化合物作为细胞周期蛋白依赖性激酶1(CDK1)抑制剂:对其结合取向和构效关系的见解
PLoS One. 2016 Aug 12;11(8):e0161111. doi: 10.1371/journal.pone.0161111. eCollection 2016.
蛋白质激酶抑制剂复合物的分子动力学:有效的结构信息。
Curr Pharm Des. 2012;18(20):2946-63. doi: 10.2174/138161212800672705.
4
Identification of glycogen synthase kinase-3 inhibitors with a selective sting for glycogen synthase kinase-3α.鉴定糖原合酶激酶-3 的抑制剂,具有选择性针对糖原合酶激酶-3α 的作用。
J Med Chem. 2012 May 10;55(9):4407-24. doi: 10.1021/jm300309a. Epub 2012 May 1.
5
Study of differences in the VEGFR2 inhibitory activities between semaxanib and SU5205 using 3D-QSAR, docking, and molecular dynamics simulations.使用 3D-QSAR、对接和分子动力学模拟研究 semaxanib 和 SU5205 对 VEGFR2 抑制活性的差异。
J Mol Graph Model. 2012 Feb;32:39-48. doi: 10.1016/j.jmgm.2011.10.005. Epub 2011 Oct 20.
6
Investigation of the differences in activity between hydroxycycloalkyl N1 substituted pyrazole derivatives as inhibitors of B-Raf kinase by using docking, molecular dynamics, QM/MM, and fragment-based de novo design: study of binding mode of diastereomer compounds.利用对接、分子动力学、QM/MM 和基于片段的从头设计研究羟基环烷基 N1 取代吡唑衍生物作为 B-Raf 激酶抑制剂的活性差异:非对映异构体化合物结合模式研究。
J Chem Inf Model. 2011 Nov 28;51(11):2920-31. doi: 10.1021/ci200306w. Epub 2011 Oct 31.
7
Binding studies and quantitative structure-activity relationship of 3-amino-1H-indazoles as inhibitors of GSK3β.3-氨基-1H-吲唑类化合物作为 GSK3β 抑制剂的结合研究与定量构效关系。
Chem Biol Drug Des. 2011 Oct;78(4):631-41. doi: 10.1111/j.1747-0285.2011.01186.x. Epub 2011 Aug 25.
8
CORAL: quantitative structure-activity relationship models for estimating toxicity of organic compounds in rats.珊瑚:用于估计大鼠体内有机化合物毒性的定量构效关系模型。
J Comput Chem. 2011 Sep;32(12):2727-33. doi: 10.1002/jcc.21848. Epub 2011 Jun 8.
9
Docking and quantitative structure-activity relationship studies for 3-fluoro-4-(pyrrolo[2,1-f][1,2,4]triazin-4-yloxy)aniline, 3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)aniline, and 4-(4-amino-2-fluorophenoxy)-2-pyridinylamine derivatives as c-Met kinase inhibitors.对接和定量构效关系研究 3-氟-4-(吡咯并[2,1-f][1,2,4]三嗪-4-基氧基)苯胺、3-氟-4-(1H-吡咯并[2,3-b]吡啶-4-基氧基)苯胺和 4-(4-氨基-2-氟苯氧基)-2-吡啶基胺衍生物作为 c-Met 激酶抑制剂。
J Comput Aided Mol Des. 2011 Apr;25(4):349-69. doi: 10.1007/s10822-011-9425-1. Epub 2011 Apr 13.
10
coral Software: QSAR for Anticancer Agents.coral 软件:抗癌药物的定量构效关系。
Chem Biol Drug Des. 2011 Jun;77(6):471-6. doi: 10.1111/j.1747-0285.2011.01117.x. Epub 2011 May 4.